For the past 20 years or so, the backbone of therapy to prevent worsening kidney function in patients with diabetes was ACE-inhibitors. But all of a sudden, a flurry of studies showing the benefits of a new class of agents – the SGLT-2 inhibitors – promise to change the standard of care with which we’ve all become so complacent.